Key Takeaways:
- Alphatec Holdings, Inc. (ATEC) has secured exclusive U.S. rights to Theradaptive’s OsteoAdapt platform for spinal fusion
- The partnership represents a landmark regenerative medicine collaboration in the spine industry
- Theradaptive has initiated a Series B investment round to accelerate the expansion of its proprietary protein-engineering platform
- The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity
- OsteoAdapt’s targeted approach has the potential to make traditional allograft and synthetic alternatives obsolete
Introduction to the Partnership
The partnership between Alphatec Holdings, Inc. (ATEC) and Theradaptive, Inc. marks a significant milestone in the development of regenerative medicine solutions for spinal fusion. ATEC, a leading provider of innovative solutions for spine surgery, has secured exclusive U.S. rights to Theradaptive’s OsteoAdapt platform, a breakthrough technology that leverages proprietary AMP2 protein technology to promote bone regeneration. This partnership is structured to deliver long-term value through a combination of upfront and milestone payments and a perpetual royalty structure.
The Technology Behind OsteoAdapt
OsteoAdapt is currently being evaluated in clinical trials in spine and dental applications and has received three FDA Breakthrough Device Designations, underscoring its potential to address significant unmet medical needs in bone regeneration. The technology has the potential to revolutionize the treatment of spinal fusion by providing a more effective and sustainable solution for patients. With its proprietary AMP2 protein technology, OsteoAdapt is poised to set a new standard for clinical distinction in spine surgery.
Theradaptive’s Series B Financing Initiation
To support the completion of clinical studies and rapid scaling of its technology platform alongside the ATEC partnership, Theradaptive has launched a Series B investment round. This capital will facilitate the advancement of the OASIS Pivotal trial in spinal fusion and the manufacturing scale-up and build-out in support of future commercialization. The Series B financing will enable Theradaptive to accelerate the development of its proprietary protein-engineering platform and bring its innovative solutions to market more quickly.
Market Opportunity and Growth Potential
The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity. OsteoAdapt’s targeted approach represents a paradigm shift intended to make traditional allograft and synthetic alternatives obsolete. With ATEC’s commercial reach and Theradaptive’s innovative technology, the partnership is well-positioned to capitalize on this significant market opportunity. The sustained sales growth from ATEC’s sales force provides confidence in maximizing market penetration and returning value to Theradaptive with the ongoing royalties.
About Alphatec Holdings, Inc. and Theradaptive, Inc.
Alphatec Holdings, Inc. is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. The company’s Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with its expanding InformatiX platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. Theradaptive, Inc. is a privately held, clinical-stage biologics company developing protein therapeutics for spine, orthopedics, dental, and soft tissue repair and targeted therapeutics in diverse areas such as immuno-oncology.
Forward-Looking Statements and Conclusion
The partnership between ATEC and Theradaptive represents a significant milestone in the development of regenerative medicine solutions for spinal fusion. While there are risks and uncertainties associated with the partnership, the potential commercial success and financial impact of the OsteoAdapt technology are substantial. As the companies move forward with the partnership and the Series B financing, they are poised to bring innovative solutions to the market and capitalize on the significant market opportunity in the U.S. spine surgery market.